These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 20335367)
1. Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer. Chan A; Miles DW; Pivot X Ann Oncol; 2010 Dec; 21(12):2305-2315. PubMed ID: 20335367 [TBL] [Abstract][Full Text] [Related]
2. A network meta-analysis on the efficacy of HER2-targeted agents in combination with taxane-containing regimens for treatment of HER2-positive metastatic breast cancer. Xie BJ; Zhu LN; Ma C; Li JB; Dong L; Zhu ZN; Ding T; Gu XS Breast Cancer; 2020 Mar; 27(2):186-196. PubMed ID: 31529262 [TBL] [Abstract][Full Text] [Related]
3. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311 [TBL] [Abstract][Full Text] [Related]
4. First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients. Smith IE; Pierga JY; Biganzoli L; Cortés-Funes H; Thomssen C; Pivot X; Fabi A; Xu B; Stroyakovskiy D; Franke FA; Kaufman B; Mainwaring P; Pienkowski T; De Valk B; Kwong A; González-Trujillo JL; Koza I; Petrakova K; Pereira D; Pritchard KI; Ann Oncol; 2011 Mar; 22(3):595-602. PubMed ID: 20819780 [TBL] [Abstract][Full Text] [Related]
5. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer. Wagner AD; Thomssen C; Haerting J; Unverzagt S Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517 [TBL] [Abstract][Full Text] [Related]
6. Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial. Hamberg P; Bos MM; Braun HJ; Stouthard JM; van Deijk GA; Erdkamp FL; van der Stelt-Frissen IN; Bontenbal M; Creemers GJ; Portielje JE; Pruijt JF; Loosveld OJ; Smit WM; Muller EW; Schmitz PI; Seynaeve C; Klijn JG; Clin Breast Cancer; 2011 Apr; 11(2):103-13. PubMed ID: 21569996 [TBL] [Abstract][Full Text] [Related]
7. Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer. Lück HJ; Lübbe K; Reinisch M; Maass N; Feisel-Schwickardi G; Tomé O; Janni W; Aydogdu M; Neunhöffer T; Ober A; Aktas B; Park-Simon TW; Schumacher C; Höffkes HG; Illmer T; Wagner H; Mehta K; von Minckwitz G; Nekljudova V; Loibl S Breast Cancer Res Treat; 2015 Jan; 149(1):141-9. PubMed ID: 25519041 [TBL] [Abstract][Full Text] [Related]
8. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. Miles DW; Chan A; Dirix LY; Cortés J; Pivot X; Tomczak P; Delozier T; Sohn JH; Provencher L; Puglisi F; Harbeck N; Steger GG; Schneeweiss A; Wardley AM; Chlistalla A; Romieu G J Clin Oncol; 2010 Jul; 28(20):3239-47. PubMed ID: 20498403 [TBL] [Abstract][Full Text] [Related]
9. Taxanes and gemcitabine doublets in the management of HER-2 negative metastatic breast cancer: towards optimization of association and schedule. Metro G; Fabi A; Russillo M; Papaldo P; De Laurentiis M; Ferretti G; Pellegrini D; Nuzzo C; Graziano V; Vici P; Introna M; Felici A; Cognetti F; Carlini P Anticancer Res; 2008; 28(2B):1245-58. PubMed ID: 18505062 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of taxanes rechallenge in first-line treatment of early metastatic relapse of patients with HER2-negative breast cancer previously treated with a (neo)adjuvant taxanes regimen: A multicentre retrospective observational study. Vasseur A; Carton M; Guiu S; Augereau P; Uwer L; Mouret-Reynier MA; Levy C; Eymard JC; Ferrero JM; Leheurteur M; Goncalves A; Robert M; De La Motte Rouge T; Bachelot T; Petit T; Debled M; Grinda T; Desmoulins I; Vanlemmens L; Nicolaï V; Simon G; Cabel L Breast; 2022 Oct; 65():136-144. PubMed ID: 35944353 [TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer. Bullock K; Blackwell K Oncologist; 2008 May; 13(5):515-25. PubMed ID: 18515736 [TBL] [Abstract][Full Text] [Related]
12. Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials. Valachis A; Polyzos NP; Patsopoulos NA; Georgoulias V; Mavroudis D; Mauri D Breast Cancer Res Treat; 2010 Jul; 122(1):1-7. PubMed ID: 20063120 [TBL] [Abstract][Full Text] [Related]
13. Phase II multicenter study of docetaxel and bevacizumab with or without trastuzumab as first-line treatment for patients with metastatic breast cancer. Schwartzberg LS; Badarinath S; Keaton MR; Childs BH Clin Breast Cancer; 2014 Jun; 14(3):161-8. PubMed ID: 24566467 [TBL] [Abstract][Full Text] [Related]
14. [Bevacizumab and taxanes in the first-line treatment of metastatic breast cancer : overall survival and subgroup analyses of the ATHENA study in France]. Pierga JY; Delva R; Pivot X; Espié M; Dalenc F; Serin D; Veyret C; Lortholary A; Gligorov J; Joly K; Hernandez J; Hardy-Bessard AC Bull Cancer; 2014 Sep; 101(9):780-8. PubMed ID: 25295737 [TBL] [Abstract][Full Text] [Related]
15. [Safety and efficacy of bevacizumab combined with taxanes in the first-line treatment of metastatic breast cancer: ATHENA study-France]. Hardy-Bessard AC; Delva R; Pivot X; Espié M; Dalenc F; Coulon Sfairi MA; Monnier A; Serin D; Veyret C; Lortholary A; Pavlyuk M; Kockler L; Pierga JY Bull Cancer; 2012 Jun; 99(6):609-18. PubMed ID: 22665515 [TBL] [Abstract][Full Text] [Related]
16. Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer. Clavarezza M; Turazza M; Aitini E; Saracchini S; Garrone O; Durando A; De Placido S; Bisagni G; Levaggi A; Bighin C; Restuccia E; Scalamogna R; Galli A; Del Mastro L Breast; 2013 Aug; 22(4):470-5. PubMed ID: 23642526 [TBL] [Abstract][Full Text] [Related]
17. How to maximize the efficacy of taxanes in breast cancer. Tubiana-Hulin M Cancer Treat Rev; 2005; 31 Suppl 4():S3-9. PubMed ID: 16360546 [TBL] [Abstract][Full Text] [Related]
18. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. Brufsky AM; Hurvitz S; Perez E; Swamy R; Valero V; O'Neill V; Rugo HS J Clin Oncol; 2011 Nov; 29(32):4286-93. PubMed ID: 21990397 [TBL] [Abstract][Full Text] [Related]
19. Role of taxane and anthracycline combination regimens in the management of advanced breast cancer: a meta-analysis of randomized trials. Zheng R; Han S; Duan C; Chen K; You Z; Jia J; Lin S; Liang L; Liu A; Long H; Wang S Medicine (Baltimore); 2015 May; 94(17):e803. PubMed ID: 25929935 [TBL] [Abstract][Full Text] [Related]
20. SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer. Mayer EL; Dhakil S; Patel T; Sundaram S; Fabian C; Kozloff M; Qamar R; Volterra F; Parmar H; Samant M; Burstein HJ Ann Oncol; 2010 Dec; 21(12):2370-2376. PubMed ID: 20497961 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]